{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:24:47Z","timestamp":1791901487211,"version":"4.3.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Patient Care and STDs"],"published-print":{"date-parts":[[2015,7]]},"abstract":"<jats:p>Medication adherence is a major determinant of antiretroviral (ARV) treatment success and a significant challenge for HIV-positive patients, yet a well-defined adherence threshold to maintain virologic suppression on current ARV regimens remains unclear. The present study evaluated 1915 Kaiser Permanente Southern California HIV-positive patients on one of three regimen types: (1) emtricitabine\u2013tenofovir\u2013efavirenz (FTC-TDF-EFV); (2) emtricitabine\u2013tenofovir (FTC-TDF) and raltegravir (RAL); and (3) FTC-TDF and a boosted protease inhibitor, either darunavir (DRV) or atazanavir (ATV), to compare virologic failure rates between patients with varying levels of adherence to the regimens. Medication possession ratios (MPRs) were calculated to determine adherence, and HIV RNA PCR levels drawn 12\u201318 months after the initial pharmacy claim for the measured drug were used to determine virologic failure, which was defined as two consecutive HIV RNA PCR measurements \u2265200 copies\/mL. Adherence was inversely related to virologic failure, with an 80\u201390% MPR threshold resulting in no more than 3.5% virologic failure rate. In comparison, \u226590% MPR yielded no more that 1.1% virologic failure rate. Although the gold-standard adherence threshold for older ARV regimens has been 95%, an 80\u201390% MPR appears sufficient to maintain virologic suppression in patients treated with these three ARV regimen types.<\/jats:p>","DOI":"10.1089\/apc.2014.0165","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T09:26:46Z","timestamp":1433410006000},"page":"384-388","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":68,"title":["Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types"],"prefix":"10.1177","volume":"29","author":[{"given":"Lindsay L.","family":"Gordon","sequence":"first","affiliation":[{"name":"Kaiser Permanente Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derenik","family":"Gharibian","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Chong","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California"},{"name":"Kaiser Permanente Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chun","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Southern California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2015,7,1]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"15","article-title":"Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study","author":"May M","year":"2012","unstructured":"May M, , Gompels M, , Sabin C. Life expectancy of HIV-1-positive individuals approaches normal conditional on response to antiretroviral therapy: UK Collaborative HIV Cohort Study. J Int AIDS Soc, 2012; 15.","journal-title":"J Int AIDS Soc"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200106150-00015"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-133-1-200007040-00004"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e318050d8c2"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn020"},{"key":"e_1_3_3_7_2","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents Department of Health and Human Services . Guidelines for the use of antiretroviral agents in HIV-1-Infected adults and adolescents. Guidelines]. May 1 2014; http:\/\/aidsinfo.nih.gov\/ContentFiles\/AdultandAdolescentGL.pdf (Last accessed May20 2014)."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.7961"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/426595"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/507526"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P587"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/09540120701694006"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1331\/JAPhA.2012.11112"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq167"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(96)00268-5"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0126"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2013.0221"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0007196"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.3851\/IMP2084"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31819675e9"}],"container-title":["AIDS Patient Care and STDs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2014.0165","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/apc.2014.0165","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/apc.2014.0165","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T18:02:43Z","timestamp":1777399363000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/apc.2014.0165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["10.1089\/apc.2014.0165"],"URL":"https:\/\/doi.org\/10.1089\/apc.2014.0165","relation":{},"ISSN":["1087-2914","1557-7449"],"issn-type":[{"value":"1087-2914","type":"print"},{"value":"1557-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]}}}